HC Wainwright Has Negative Estimate for ALDX FY2029 Earnings

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) – Investment analysts at HC Wainwright reduced their FY2029 earnings per share estimates for Aldeyra Therapeutics in a report released on Monday, May 11th. HC Wainwright analyst M. Caufield now anticipates that the biotechnology company will earn $0.15 per share for the year, down from their prior estimate of $0.24. HC Wainwright has a “Neutral” rating and a $2.00 price target on the stock. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.44) per share.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.07.

Several other equities analysts have also recently issued reports on ALDX. Wall Street Zen cut Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. BTIG Research restated a “buy” rating on shares of Aldeyra Therapeutics in a research report on Tuesday, March 17th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Aldeyra Therapeutics has a consensus rating of “Hold” and an average price target of $5.50.

Aldeyra Therapeutics Trading Up 1.7%

Shares of ALDX opened at $1.76 on Tuesday. Aldeyra Therapeutics has a 52 week low of $1.07 and a 52 week high of $6.18. The firm has a market cap of $106.16 million, a price-to-earnings ratio of -3.09 and a beta of 1.16. The stock has a 50 day moving average of $2.47 and a 200-day moving average of $4.12.

Insider Buying and Selling

In other news, Director Richard Douglas purchased 70,000 shares of the company’s stock in a transaction on Thursday, March 19th. The shares were bought at an average price of $1.40 per share, for a total transaction of $98,000.00. Following the completion of the purchase, the director owned 195,000 shares of the company’s stock, valued at $273,000. This trade represents a 56.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 8.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Krilogy Financial LLC bought a new stake in shares of Aldeyra Therapeutics during the first quarter valued at about $26,000. Abel Hall LLC bought a new position in shares of Aldeyra Therapeutics in the first quarter valued at approximately $26,000. Chicago Partners Investment Group LLC acquired a new position in shares of Aldeyra Therapeutics during the first quarter valued at approximately $33,000. Caption Management LLC raised its holdings in Aldeyra Therapeutics by 110.6% during the second quarter. Caption Management LLC now owns 12,664 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 132,358 shares in the last quarter. Finally, Inspirion Wealth Advisors LLC acquired a new stake in Aldeyra Therapeutics in the fourth quarter worth approximately $52,000. Institutional investors and hedge funds own 59.71% of the company’s stock.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.